{"id":"immuncell-lc","safety":{"commonSideEffects":[{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Chills"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Infusion-related reactions"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Immuncell-LC involves ex vivo activation and expansion of lymphocytes derived from the patient's own blood, which are then reinfused to boost cellular immune responses against cancer. The therapy leverages the patient's endogenous immune system by culturing and amplifying cytotoxic T cells and natural killer cells to target malignant cells. This autologous approach aims to provide personalized immunotherapy with reduced rejection risk.","oneSentence":"Immuncell-LC is an autologous cell therapy that activates and expands a patient's own immune cells to enhance anti-tumor immunity.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:49:49.916Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Advanced gastric cancer"},{"name":"Colorectal cancer"}]},"trialDetails":[{"nctId":"NCT00807027","phase":"PHASE3","title":"Clinical Trial to Assess the Efficacy and Safety of 'Immuncell-LC' With Temozolomide in Newly Diagnosed Glioblastoma of Korea","status":"COMPLETED","sponsor":"GC Cell Corporation","startDate":"2008-12-05","conditions":"Glioblastoma","enrollment":180},{"nctId":"NCT06620510","phase":"","title":"Retrospective Study of Long-Term Survival of \"Immuncell-LC\" in Patients Undergoing Curative Resection for HCC in Korea","status":"COMPLETED","sponsor":"GC Cell Corporation","startDate":"2024-09-30","conditions":"Hepatocellular Carcinoma","enrollment":230},{"nctId":"NCT00965718","phase":"PHASE2","title":"Evaluate the Efficacy and Safety of Activated T-lymphocyte Cell Therapy in Advanced Pancreatic Cancer","status":"COMPLETED","sponsor":"GC Cell Corporation","startDate":"2009-09","conditions":"Pancreatic Cancer","enrollment":20},{"nctId":"NCT00699816","phase":"PHASE3","title":"Efficacy and Safety of Immuncell-LC Group and Non-treatment Group in Hepatocelluar Carcinoma Patients","status":"COMPLETED","sponsor":"GC Cell Corporation","startDate":"2008-07","conditions":"Hepatocellular Carcinoma","enrollment":230},{"nctId":"NCT01897610","phase":"PHASE2","title":"Efficacy and Safety of 'Immuncell-LC Group' and 'Non-treatment Group' in Nexavar Treated Patients for Advanced HCC","status":"COMPLETED","sponsor":"GC Cell Corporation","startDate":"2013-12","conditions":"Advanced Hepatocellular Carcinoma","enrollment":40},{"nctId":"NCT01890291","phase":"","title":"Long Term Follow-Up Study of Immuncell-LC Group and Non-Treatment Group in Hepatocellular Carcinoma Patients.","status":"COMPLETED","sponsor":"GC Cell Corporation","startDate":"2013-06","conditions":"Hepatocellular Carcinoma","enrollment":162},{"nctId":"NCT03983967","phase":"PHASE1, PHASE2","title":"Evaluate the Efficacy and Safety of 'Immuncell-LC' in Patients Undergoing Liver Transplantation","status":"COMPLETED","sponsor":"GC Cell Corporation","startDate":"2019-01-24","conditions":"Liver Transplantation","enrollment":19},{"nctId":"NCT02856815","phase":"PHASE2","title":"Safety and Efficacy of \"Immuncell-LC\" in TACE Therapy","status":"COMPLETED","sponsor":"GC Cell Corporation","startDate":"2018-05-28","conditions":"Carcinoma, Hepatocellular","enrollment":76},{"nctId":"NCT04969731","phase":"PHASE3","title":"Safety and Efficacy of Immuncell-LC With Gemcitabine in Resectable Pancreatic Cancer","status":"RECRUITING","sponsor":"GC Cell Corporation","startDate":"2021-09-07","conditions":"Pancreatic Ductal Adenocarcinoma","enrollment":408},{"nctId":"NCT05053295","phase":"NA","title":"Investigator-initiated Pilot Study to Investigate the Efficacy and Safety of Immuncell-LC in Combination With Nivolumab (Opdivo) in Subjects With Advanced or Recurrent Gastric Cancer","status":"UNKNOWN","sponsor":"Gangnam Severance Hospital","startDate":"2021-07-02","conditions":"Relapsed or Advanced Gastric Adenocarcinoma, Gastro-esophageal Junction Cancer","enrollment":20},{"nctId":"NCT01802138","phase":"NA","title":"A Pilot Study of Activated T Cell Therapy for Refractory/Relapsed Neuroblastoma","status":"COMPLETED","sponsor":"Seoul National University Hospital","startDate":"2013-02","conditions":"Neuroblastoma","enrollment":6},{"nctId":"NCT03220984","phase":"PHASE2","title":"The Safety and Efficacy Test of Immuncell-LC to Treat Refractory Metastatic Colorectal Cancer","status":"UNKNOWN","sponsor":"Gangnam Severance Hospital","startDate":"2017-03-16","conditions":"Metastatic Colorectal Cancer","enrollment":28}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Activated T lymphocyte","Autologous activated T lymphocyte"],"phase":"phase_3","status":"active","brandName":"Immuncell-LC","genericName":"Immuncell-LC","companyName":"GC Cell Corporation","companyId":"gc-cell-corporation","modality":"Biologic","firstApprovalDate":"","aiSummary":"Immuncell-LC is an autologous cell therapy that activates and expands a patient's own immune cells to enhance anti-tumor immunity. Used for Advanced gastric cancer, Colorectal cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}